iMatrix-511 Stem Cell Culture Substrate

iMatrix-511 is a highly purified and refined laminin-511 E8 fragments, produced in CHO cells.

iMatrix-511 features make it an ideal matrix for pluripotent stem cell culture:

• Promotes greater stem cell adhesion than all other matrix proteins that have been tested
• Easy to use (liquid format)
• E8 fragments retain integrin binding specificity and capacity and display higher potency than natural Laminin-511
• Equivalent performance, but lower cost than the legacy iMatrix-511 product

Laminin is localized to the basement membrane and plays a key role in cell adhesion and proliferation. Laminin-511 (α5, β1 laminin) binds to integrin α6β1 to promote cell signaling. Laminin-511 provides an ideal matrix for the proliferation of a wide variety of cell types including stem and iPS cells.

iMatrix-511 is functionally equivalent to iMatrix-511 SILK (Cat. No. NP892-021). The only difference is the expression system used for bioproduction. The iMatrix-511 SILK product is produced in recombinant silkworm cocoon, while iMatrix-511  is produced in CHO-S cells. Both are E8 fragments that have been purified using the same processes.

Matrixome company name and logo and iMatrix brand name are the property of Matrixome Corp., Japan.

Specifications

Product Name: iMatrix-511 Stem Cell Culture Substrate

Catalog Numbers:

• NP892-011
• NP892-012

Sizes:

• NP892-011: 2 × 175 µg
• NP892-012: 6 × 175 µg

Molecular Weight: 150 kDa

Purity: > 95 % pure

Formulation: Purified Laminin-511 E8 proteolytic fragment

Storage and Stability: Store at 4 °C and protect from light exposure. Stable for 2 years from manufacturing date.

Concentration: 500 µg/mL

Source: CHO cells

Quality Control: Integrin binding K_d < 10 nM

Sterility: Sterile

Notice To Purchaser: REPROCELL is a licensed distributor of Matrixome cell culture substrates to the global market.

Recommended Usage: iMatrix-511 is suitable for use as a substrate for culture of various cell types, including ES/iPS cells.

Manufacturer: Matrixome Corporation (Japan)

Safety Data Sheet:

• NP892-01 Safety Data Sheet

Specifications Sheets:

• NP892-01 Specifications Sheet

Product Flyers:

• iMatrix™ 511 Cell Culture Substrate
• iMatrix™ Cell Culture Substrates

Protocols:

• Nippi iMatrix-511 Cell Culture Substrate: Use with Stemgent® StemRNA™ 3^rd Gen Reprogramming Kit and NutriStem™ hPSC XF Culture Medium

1. Takayama K. et al., "Laminin 411 and 511 promote the cholangiocyte differentiation of human induced pluripotent stem cells". Biochemical and Biophysical Research Commun.474 (1): 91-96 (2016).
2. Nishimura K. et al., "Estradial facilitates functional integration of iPSC-derived dopaminergic neurons into striatal neuronal circuits via activation of integrin a5b1". Stem Cell Reports6  (4): 511-524 (2016).
3. Matsuno K. et al., "Redefining definitive endoderm subtypes by robust induction of human induced pluripotent stem cells". Differentiation2016.04.002.
4. Hayashi R. et al., "Co-ordinated ocular development from human iPS cells and recovery of corneal function". Nature531, 368-80 (2016),
5. Sasaki K. et al., "Robust in vitro induction of human germ cell fate from pluripotent stem cells". Cell Stem Cell 17 (2):178-194 (2015).
6. Okumura N. et al., "Laminin-511 and -521 enable efficient in vitro expansion of human corneal endothelial cells". Invest Ophthalmal Vis Sci.56 (5), 2933-42 (2015).
7. Nakagawa M. et al., "A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells". Scientific Reports 4: 3594 (2014).
8. Miyazaki T. et al. "Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells." Nature Communications 3: 1236 (2012).
9. Taniguchi Y. et al., "The C-terminal region of laminin β-chains modulates the integrin-binding affinities of laminins." J. Biol. Chem.284 (12): 7820-31 (2009).
10. Ido H. et al., "The requirement of the glutamic acid residue at the third position from the carboxyl termini of the laminin gamma-chains in integrin-binding by laminins." J. Biol. Chem.282 (15): 11144-54 (2017).

Additional Publications

• Leonardi O; Lewerissa E; Aprile D; Barakat TS; Culotta L; Deng R; Haazen L; Linda K; Majoie M; Mordelt A; Ortale A; Oudakker A; Prazzoli F; Puvogel S; Scheefhals N; Schelhaus HJ; Schoenmaker C; van Jugte E; van Bokhoven H; Verhoeven J; Vitriolo A; Boeckx C; Testa G; Kasri NN. CHD2 Dosage Ties Autolysosomal Pathway to Cortical Maturation in Disease and Evolution. bioRxiv :https://doi.org/10.1101/2025.01.21.634145 (2025).
• Nagawa M; Nogi M; Doi H; Ohno H; Mochizuki M; Hayashi K'' Saito H. MDM4 enables efficient human iPS cell generation from PBMCs using synthetic RNAs. Research Square https://doi.org/10.21203/rs.3.rs-6250001/v1 (2025).
• Jiang Y; Devito LG; Muntoni F; Healy L; Tedesco FS. Generation of a human induced pluripotent stem cell line (CRICKi021-A) from a patient with Ullrich congenital muscular dystrophy carrying a pathogenic mutation in the COL6A1 gene. Stem Cell Research 83:103648 (2025).
• Devito LG; Lionello VM; Muntoni F; Tedesco FS; Healy L. Generation of an MTM1-mutant iPSC line (CRICKi008-A) from an individual with X-linked myotubular myopathy (XLMTM). Stem Cell Res 69:102079 (2023).
• Devito LG; Zanjani ZS; Evans JR; Scardamaglia A; Houlden H; Gandhi S; Healy L. Generation of TWO G51D SNCA missense mutation iPSC lines (CRICKi011-A, CRICKi012-A) from two individuals at risk of Parkinson's disease. Stem Cell Res 71:103134 (2023).
• Neumayer G; Torkelson JL; Li S; McCarthy K; Zhen HH; Vangipuram M; Jackow J; Rami A; Hansen C; Guo Z; Gaddam S; Pappalardo A; Li L; Cramer A; Roy KR; Nguyen TM; Tanabe K: McGrath PS; Bruckner A; Bilousova G; Roop D; Bailery I; Tang JY; Christiano A; Steinmetz LM; Wernig M; Oro AE. A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa. bioRxiv doi.org/10.1101/2023.02.28.529447: (2023).
• Surana S; Villarroel-Campos D; Panzi C; Novoselov SS: Richter S; Zanotti G; Schiavo G. The tyrosine phosphatase LAR acts as a receptor of the nidogen-tetanus toxin complex. bioRxiv doi.org/10.1101/2023.02.03.526966: (2023).
• Islam SMR; Maeda T; Tamaoki N; Good ML; Kishton RJ; Paria BC; Ya Z; Bosch-Marce M; Bedanova NM; Liu C; Kruhlak MJ; Restifo NP; Vizcardo R. Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells. Cancer Res Commun 3:917 (2023).
• Bakare AB; Meshrkey F; Lowe B; Molder C; Rao RR; Zhan J; Iyer S. MitoCellPhe reveals mitochondrial morphologies in single fibroblasts and clustered stem cells. Am J Phys Cell Physiol 321:C735-748 (2021).
• Meshrkey F; Ayuso AC; Rao RR; Iyer S. Quantitative analysis of mitochondrial morphologies in human induced pluripotent stem cells for Leigh syndrome. Stem Cell Res 57:102572 (2021).
• Devito LG; Cooper F; D'Angelo I; Smith J; Healy L. Generation of FOUR iPSC lines (CRICKi004-A; CRICKi005-A; CRICKi006-A, CRICKi007-A) from Spinal muscle atrophy patients with lower extremity dominant (SMALED) phenotype. Stem Cell Res 65:102954 (2022).
• Supakul S; Leventoux N; Tabuchi J; Mimura M; Ito D; Maeda S; Okano H. Establishment of KEIOi005-A iPSC line from urine-derived cells (UDCs) of a mild Alzheimer’s disease (AD) donor with multiple risk SNPs for sporadic Alzheimer’s disease (sAD). Stem Cell Res 62:102802 (2022).
• Rajasingh S; Sigamani V; Selvam V; Gurusamy S; Kirankumar S; Vasanthan J; Rajasingh J. Comparative analysis of human induced pluripotent stem cell-derived mesenchymal stem cells and umbilical cord mesenchymal stem cells. J Cell Mol Med 25:8904 (2021).
• Fiacco E; Alowaysi M; Astro V; Adamo A. Derivation of two naturally isogenic iPSC lines (KAUSTi006-A and KAUSTi006-B) from a mosaic Klinefelter Syndrome patient (47-XXY/46-XY). Stem Cell Res 49:102049 (2020).
• Alowaysi M; Fiacco E; Astro V; Adamo A. Establishment of iPSC lines from a high-grade Klinefelter Syndrome patient (49-XXXXY) and two genetically matched healthy relatives (KAUSTi003-A, KAUSTi004-A, KAUSTi004-B, KAUSTi005-A, KAUSTi005-B, KAUSTi005-C). Stem Cell Res 49:102008 (2020).
• Shimada M; Tsukada K; Kagawa N; Matsumoto Y. Reprogramming and differentiation-dependent transcriptional alteration of DNA damage response and apoptosis genes in human induced pluripotent stem cells. J Radiation Res 2019:1-10 (2019).
• Nakajima M; Yoshimatsu S; Sato T; Nakamura M; Okahara J; Sasaki E; Shiozawa S; Okano H. Establishment of induced pluripotent stem cells from common marmoset fibroblasts by RNA-based reprogramming. Biochem Biophys Research Commun in press:https://doi.org/10.1016/j.bbrc.2019.05.175 (2019).
• Liu L-P; Li Y-M; Guo N-N; LI S; Ma X; Zhang Y-X; Gao Y; Huang J-L; Zheng D-X; Wang L-Y; Xu H; Hui L; Zheng Y-W. Therapeutic Potential of Patient iPSC-Derived iMelanocytes in Autologous Transplantation. Cell Reports 27:455-466.e5 (2019).
• Harmanto Y; Maki T; Yakagi Y; Miyamoto S; Takahashi J. Xeno‐free culture for generation of forebrain oligodendrocyte precursor cells from human pluripotent stem cells. J Neuro Res 2019:1-18 (2019).
• Tsujimara T; Takase O; Yoshikawa M; Sano E; Hayashi M; Hoshi K; Takato T; Toyoda A; Okano H; Hishikawa K. Controlling gene activation by enhancers through a drug-inducible topological insulator. bioRxiv http://dx.doi.org/10.1101/534073 (2019).